Patient Education
Share your love
Orasis Pharmaceuticals introduces starter packs of pilocarpine hydrochloride ophthalmic solution 0.4% | Ophthalmology Times
(Image Credit: AdobeStock/bankoo) Orasis Pharmaceuticals announced the availability of Starter Packs of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% to “broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals.”1…
Clinical and Biologic Distinctions in Managing Retinal Vascular Diseases | Ophthalmology Times
This discussion explores key clinical distinctions that guide treatment decisions across retinal vascular diseases, with a particular focus on differentiating management strategies for branch versus central retinal vein occlusion (BRVO vs. CRVO) and diabetic macular edema (DME). The panel emphasizes…
Defining Retinal Vascular Diseases AMD, DME, RVO | Ophthalmology Times
The discussion opens with an overview of the evolving anti-VEGF treatment landscape for retinal vascular diseases, highlighting key distinctions among neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The panel examines how disease mechanisms,…
Regeneron’s EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly…
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant | Ophthalmology Times
(Image Credit: AdobeStock/Anna) Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical Center in Haifa, Israel. The procedure was conducted as part of the company’s ongoing phase 1 clinical trial. PB-001 is…
Limitations of Current Dry Eye Therapies | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Treatment Selection in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Harrow completes acquisiton of Melt Pharmaceuticals | Ophthalmology Times
(Image Credit: AdobeStock/Parradee) Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and MELT-400 based on the Zydis ODT (oral dissolving tablet) drug delivery platform. Melt will now be fully integrated into Harrow’s operations to…
Brain Stimulation Boosts Vision Recovery After Stroke
A new study from researchers at EPFL introduces a promising non-invasive brain stimulation technique aimed at restoring visual function in stroke patients with hemianopia. The treatment combines visual training with targeted neuromodulation, offering a novel approach to visual rehabilitation in…
Trifocal IOL for Presbyopia Correction
Presbyopia continues to be one of the most significant visual limitations following cataract surgery, even with the use of advanced monofocal or extended-depth intraocular lenses (IOLs). Despite technological progress, achieving consistent vision across near, intermediate and far distance foci remains…